AzTrials
AzTrials

Solid Tumor, AdultPhase 1NCT05866692

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study testing TY-2699a in people with Solid Tumor, Adult, run by TYK Medicines, Inc at 2 sites in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Solid Tumor, Adult
What is being tested?
TY-2699a
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
156 participants
Where
2 sitesChina
Study dates
17 Aug 2023to Oct 2026
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Be able to provide written informed consent approved by institutional review board (IRB) or independent ethics committee (IEC).
  • Age ≥18 years.
  • At the escalation stage, patients should fulfill the following criteria at Screening:
  • 1) Participants with locally advanced or metastatic solid tumors including TNBC, ER+HER2-BC, ovarian cancer, small cell lung cancer, castrate-resistant prostate cancer (CRPC), or PDAC with KRAS mutant; Or any other locally advanced or metastatic solid tumor with evidence of deregulated RB-pathway based on available molecular test results and after sponsor review to confirm eligibility as determined with prior molecular assays performed in a CLIA-certified or equivalent laboratory. (Note: ① 0% - 1% of tumor cells expressing ER or PR as negative while ≥ 1% of tumor cells expressing ER or PR as positive on IHC staining, recommended by ASCO/CAP guideline Update 2020; negative HER2 is defined as IHC 0 or 1+, or IHC 2+ but confirmed by the negative ISH, recommended by ASCO/CAP Guideline 2018; ② Genes of KRAS and other biomarkers will be detected by the Polymerase Chain Reaction (PCR) or Next-Generation Sequencing (NGS)); 2) Patients who have progressed on established standard medical anti-cancer therapies for a given tumor type or have been intolerant to such therapy, or in the opinion of the investigator have been considered ineligible for a particular form of standard therapy on medical grounds.
  • 4. At the expansion stage, patients should fulfill the following criteria at Screening :
  • 1)Cohort : TNBC patients progressed on ≥ 2 previous lines of therapy and/or other solid tumors will receive TY-2699a. ① Previous therapy can be of any nature (chemotherapy, immunotherapy, antiangiogenics, experimental therapy, etc.); ② Histologically-confirmed breast carcinoma not expressing ER, PR, and HER2 (negative ER and PR is defined as < 1% tumor cells expressing ER and PR on IHC staining, recommended by ASCO/CAP Guideline Update 2020; negative HER2 is defined as IHC staining 0 or 1+ , or IHC 2+ but confirmed by the negative ISH, recommended by ASCO/CAP Guideline 2018; negative HER2 is defined as IHC 0 or 1+, or IHC 2+ but confirmed by the negative ISH, recommended by ASCO/CAP Guideline 2018); ③ With or without BRCA mutation.
Show all 14Show fewer
  • 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and life expectancy > 3 months.
  • 6. Capability to swallow intact capsule (without chewing, crushing or opening). 7. At least 1 measurable target lesion according to Response Evaluation Criteria in Solid Tumor Version 1.1 (RECIST v1.1, Appendices 15.2 RECIST v1.1 ) determined by the investigator.
  • 8. All acute toxic effects (excluding alopecia and neuropathy associated with prior platinum-based drug therapy) of any prior therapy recovered to grade ≤1 based on NCI CTCAE v5.0.
  • 9. Baseline laboratory results fulfilling the following requirements: Absolute neutrophils count (ANC) ≥1500/mm3 (1.5×109/L) Platelets ≥100,000/mm3 (100×109/L) Hemoglobin > 90 g/L Estimated creatinine clearance ≥55 mL/min+ Total serum bilirubin <1.5 × ULN <3.0 × ULN if known Gilbert's disease Liver transaminases (AST/ALT) <2.5 × ULN; <5 × ULN if liver metastases are present ULN: upper limit normal.
  • No blood transfusion, blood products, or hematopoietic factors such as G-CSF, erythropoietin or albumin within 14 days prior to first dose.
  • Cockcroft-Gault Equation. 10. For female patients of childbearing potential, the serum or urine pregnancy test within 7 days prior to the start of TY-2699a treatment should be negative.
  • 11. Male and female patients of childbearing potential must agree to use at least two method of highly effective contraception from signing ICF, throughout the study and continued for 90 days after the last dose of TY-2699a treatment at the escalation stage or for the labeled duration of contraception of the combined approved drug fulvestrant (e.g., FASLODEX requires one-year contraception after the last dose) or PD-L1 antibody (will decide a brand approved in US before starting expansion stage) after the last dose at the expansion stage.
  • 12. Willing and able to comply with all aspects of the protocol.

Who cannot join

  • Concurrent participation in another interventional clinical trial, unless the patient at long-term follow-up period.
  • Patients with the following treatment:
  • Received undergone major surgery (except minor surgery such as appendicitis, tumor biopsy, etc.) within 4 weeks prior to the first dose.
  • Received bone marrow (equal to area of pelvis) or extensive radiation therapy within 28 days prior to the first dose; received local radiation therapy (e.g., thoracic spine and rib radiation therapy) within 7 days prior to the first dose of the study drug.
  • Received CYP3A and CYP2C8 strong inducers/strong inhibitors or p-gp glycoprotein inhibitors within 14 days prior to the first dose (see Appendices 15.3 Examples of CYP450-related Drugs/food).
  • History of proton pump inhibitors (PPIs) within 4 days prior to the first dose of TY-2699a; OR history of histamine H2 blockers within 2 days prior to the first dose of TY-2699a. Patients who are receiving and require continuation of drug therapy during the study with drugs known to prolong the QTc interval or that may cause torsades de pointes.
Show all 26Show fewer
  • Prior exposure to transcriptional kinase family CDK inhibitors, such as the CDK7 and CDK9 inhibitors SY-5609，CT-7001，Alvocidib，Dinaciclib，Seliciclib and SY-1365. Exception: Previous exposure to cell cycle CDK inhibitors such as inhibitors of CDK4 and CDK6 (ie, palbociclib) is allowed.
  • History of other previous cancer (except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected), requiring therapy within the previous 5 years
  • Patients with unstable brain metastases: Patients with CNS complications requiring urgent neurosurgical treatment (e.g., surgery, etc.) (except when surgery is completed >7 days and side effects from complications are ≤ grade 1); patients requiring glucocorticoids, mannitol or diuretics at equivalent doses greater than 4 mg of dexamethasone to control symptoms of brain metastases within 14 days prior to the first study dose; patients who have undergone whole brain radiation therapy or gamma knife within 14 days prior to the first study dose; patients with symptoms of spinal cord compression from the tumor. Note: conversely, patients with stable CNS metastasis and those who are beyond the treatment washout period of 14 days per protocol are eligible to the study.
  • Epilepsy needing treatment; having a history of psychotropic substance abuse that cannot abstain; have mental disorders (successful abstain must pass at least 2 weeks without observing withdrawal reaction).
  • Patients receiving long-term systemic immunosuppressant therapy (≤10 mg/ day of prednisone or other equivalent dose of corticosteroid inhalation or topical administration can be included).
  • Any of the following cardiac criteria:
  • Mean resting corrected QT interval (electrocardiogram interval measured from the onset of the QRS complex to the end of the T wave) for heart rate QTc > 470 msec obtained from 3 electrocardiograms, using the screening clinic electrocardiogram machine derived QTc value.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250 msec). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval during Screening.
  • Left ventricular ejection fraction (LVEF) <50%；
  • Clinically significant cardiovascular disease (either active at Screening or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥II), cerebrovascular accident or transient ischemic attack, stroke, symptomatic bradycardia, or requirement for anti-arrhythmic medication.
  • Unstable patients that may affect their safety or compliance of study, any serious or uncontrolled systemic disease including uncontrolled high blood pressure (systolic blood pressure >160mmHg, or diastolic pressure >100mmHg), uncontrolled diabetes (fasting plasma glucose >10 mmol/L), active bleeding, severe eye disease, severe psychosis, nerve, vascular, or respiratory disease.
  • Known active infections, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection, except for asymptomatic chronic HBV or HCV carriers. Active HBV, HCV, or HIV infections are defined as
  • Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥ 2000 cps/mL or 500 IU/mL; HBsAg-negative, anti-HBc-positive patients are at high risk of HBV reactivation who require suppressive antiviral therapy prior to initiation of cancer therapy
  • Anti-HCV antibody positive and HCV-RNA > upper normal limit defined by sites
  • Anti-HIV antibody positive with uncontrolled opportunistic infections; anti-HIV antibody positive with CD4+ count < 350 cells/uL that requires HIV therapy prior to the cancer treatment; other conditions allowing concurrent ART but the therapy not tolerated and that the toxicities confused with investigational drug toxicities. Note: Examples of drug-drug interactions that affect absorption, distribution, metabolism, and excretion of the TY-2699a are shown in Appendices 15.3 Examples of CYP450-related Drugs/food.
  • Diagnosed interstitial lung disease with or without symptoms, as well as conditions that may cause pulmonary toxicity or related pneumonia after using TY-2699a, or pulmonary symptoms deemed by the investigator to have high risk of developing interstitial lung disease. Note: Patients with history of prior radiation pneumonitis will not be excluded.
  • Active gastrointestinal disease with significant symptoms (e.g., gastric ulcer, Crohn's disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that will impact in ingesting, transporting, or absorbing the drug.
  • Known/suspected allergy to the composition of TY-2699a or the analogues.
  • Pregnant and breastfeeding women.
  • The Prinicpal Investigator considers that the patient is not suitable to participate in this study.

Trial locations and contacts

2 sites in 1 country.

China2 sites, 2 recruiting

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

    Beijing, Beijing Municipality, 100021

    Xu Binghe, MD, 8610-87788495, cancergep@163.com

    Xu Binghe, MD

    Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, 250117

    Sun Yuping, 0531-67626929, 13370582181@163.com

    Sun Yuping

    Recruiting

Other trials in China

About this study

Official title: A Phase I, Multicenter, Open-label Study of TY-2699a, Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumors

This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.

Read the detailed description

To assess the safety and tolerability of TY-2699a when administered as a single agent in subjects with locally advanced or metastatic solid tumors.

To determine the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) as a single agent in subjects with locally advanced or metastatic solid tumors.

To evaluate the pharmacokinetics (PK) of TY-2699a administered at single and multiple oral doses.

To assess the preliminary antitumor activity of TY-2699a as a single agent in subjects with locally advanced or metastatic solid tumors.

Being tested
TY-2699a

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TY-2699aDrug

    TY-2699a PO, BID

    Escalation stage: increased dose cohorts from low dose to MTD

    Expansion stage: The dose for the Expansion stage will be determined based on results

Study groups in NCT05866692
Study groupRoleWhat they receive
TY-2699aExperimentalEscalation stage: Multiple doses of TY-2699a as monotherapy for oral administration to find the maximum tolerated dose. Expansion stage: an optimal dose of TY-2699a for cohort expansion.
Receives: Drug: TY-2699a

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Escalation stage) Dose Limiting Toxicities (DLTs)

    Numbers of participants experiencing AEs which are defined as DLTs classfied by CTCAE v5.0.

    Measured: Within 28 days of the first dose

  2. (Escalation stage) Recommended Phase 2 Dose (RP2D)

    The RP2D is defined as the dose level chosen for the dose expansion arms, based on safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamic (PD) data collected during the dose escalation portion of the study.

    Measured: Within 28 days of the last patient dosed in escalation stage

  3. (Escalation stage) Adverse events (AEs)

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Measured: From Baseline up to 28 days after the end of the treatment

  4. (Expansion stage) Overall Response Rate (ORR)

    ORR is defined as the percentage of subjects who have a partial response (PR) or complete response (CR) to the treatment response assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

    Measured: From the date of first dose until the date of first documented progression or stable disease or the date of death from any cause, whichever came first, assessed up to 30 months.

Secondary outcomes (9)

  1. (Escalation and Expansion stage) Area under the plasma concentration time curve(AUC0-inf)

    AUC0-inf defined as the area under the plasma concentration-time curve from time 0 extrapolated to Infinite time.

    Measured: Cycle 1 Day 1 (at pre-dose) and Cycle 1 Day 28 (at pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose)(Each Cycle=28 days)

  2. (Escalation and Expansion stage) Area under the plasma concentration time curve(AUC0-t)

    AUC0-t defined as area under the plasma concentration-time curve from time 0 to time t.

    Measured: Cycle 1 Day 1 (at pre-dose) and Cycle 1 Day 28 (at pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose)(Each Cycle=28 days)

  3. (Escalation and Expansion stage) Maximum plasma concentration (Cmax)

    Cmax is the maximum (or peak) plasma concentration that the drug achieves in blood after the drug has been administered.

    Measured: Cycle 1 Day 1 (at pre-dose) and Cycle 1 Day 28 (at pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose)(Each Cycle=28 days)

  4. (Escalation and Expansion stage) Minimum plasma concentration (Cmin)

    Cmin is the minimum plasma concentration that the drug achieves in blood after the drug has been administered.

    Measured: Cycle 1 Day 1 (at pre-dose) and Cycle 1 Day 28 (at pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose)(Each Cycle=28 days)

  5. (Escalation and Expansion stage) The time to the peak concentration (Tmax)

    Tmax is defined as the time of maximum concentration of the drug in blood observed after a drug dose administration.

    Measured: Cycle 1 Day 1 (at pre-dose) and Cycle 1 Day 28 (at pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose)(Each Cycle=28 days)

  6. (Escalation and Expansion stage) Progression-free survival (PFS)

    PFS is defined as the time from randomization until first evidence of disease progression or death.

    Measured: Up to 30 months after the date of first dose.

  7. (Escalation and Expansion stage) Duration of Response (DOR)

    DOR is defined as the time from randomization to disease progression or death in patients who achieve complete or partial response.

    Measured: Up to 30 months after the date of first dose.

  8. (Escalation and Expansion stage) Overall survival (OS)

    OS is defined as the time from the start of treatment to death or the end of the study.

    Measured: Up to 30 months after the date of first dose.

  9. (Escalation stage) Overall Response Rate (ORR)

    ORR is defined as the percentage of subjects who have a partial response (PR) or complete response (CR) to the treatment response assessment in accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

    Measured: From the date of first dose until the date of first documented progression or stable disease or the date of death from any cause, whichever came first, assessed up to 30 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2023
  2. Study start17 Aug 2023
  3. Primary completionOct 2025 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential
Masking
None (open label)
Enrolment
156 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05866692
Sponsor's protocol ID
TYKM1805102
Status last verified
Aug 2023
First submitted
10 May 2023
Last updated
7 Nov 2023
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing TY-2699a in people with Solid Tumor, Adult, run by TYK Medicines, Inc at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Escalation stage) Dose Limiting Toxicities (DLTs) (time frame: Within 28 days of the first dose). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05866692.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in